We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

AutovaxID™-C Introduced by Biovest International

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Biovest International, Inc. has presented its cell culture instrument, the AutovaxID™-C, at the Cancer Research Institute's recent meeting titled "Cancer Vaccines: Barriers, Endpoints and Opportunities."

The AutovaxID-C is an automated hollow fiber cell culture instrument that collects secreted protein from cells and controls the growth of the cells automatically for 30 days or more.

Growth takes place in sterile, disposable patient specific modules that are bar coded for ease of tracking and identification.

Biovest believes that the AutovaxID-C instrument represents a significant advance in personalized medicine because it reduces the possibility of cross contamination and allows segregation of patient specific vaccine batches.

"Cancer vaccines are one of the most exciting and promising fields of personalized medicine," said Carl M. Cohen, Ph.D., Chief Operating Officer, Biovest.

"The production of a patient specific vaccine to immunize individuals against their own cancers has been a goal of investigators in both academia and industry."

"Biovest is currently testing an idiotype vaccine to treat follicular non-Hodgkin's lymphomas in a Phase 3 clinical trial."

"Our approach is unique in that it uses hybridoma technology to produce complete idiotype proteins identical to those on the tumor B cells," said Dr. Cohen.

"Results from early clinical trials are very encouraging and generating a lot of excitement in the medical community; however, there has been some concern about the challenge of producing personalized vaccines on a large scale."

"At this meeting we presented the first of a suite of instruments, designed and produced by the Biovest Advanced Instrumentation Division that automates many of the steps involved in hybridoma-based manufacturing."

"We believe that our new instruments will facilitate the large-scale manufacture of personalized vaccines. We also believe that there is a significant market potential for this instrument."